DeepMed Research

SWOG

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1956-01-01

Employees: 101

Market Cap: -

Website: http://www.swog.org

Clinical Trials

Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Phase 2

Recruiting

Conditions: Refractory T Acute Lymphoblastic Leukemia
Recurrent T Acute Lymphoblastic Leukemia

Interventions: Drug: AKR1C3-activated Prodrug OBI-3424

First Posted Date: 2020-03-19

Last Posted Date: 2024-11-07

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 39

Registration Number: NCT04315324

Locations: 🇺🇸
McFarland Clinic - Trinity Cancer Center, Fort Dodge, Iowa, United States
🇺🇸
North Memorial Medical Health Center, Robbinsdale, Minnesota, United States
🇺🇸
Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States

and more 113 locations

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

Phase 2

Active, not recruiting

Conditions: Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Interventions: Drug: Selpercatinib

First Posted Date: 2020-02-13

Last Posted Date: 2024-11-28

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 124

Registration Number: NCT04268550

Locations: 🇺🇸
Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States
🇺🇸
The Mark H Zangmeister Center, Columbus, Ohio, United States
🇺🇸
Doctors Hospital, Columbus, Ohio, United States

and more 303 locations

Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2

Withdrawn

Conditions: Lung Squamous Cell Carcinoma
Recurrent Lung Carcinoma
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Interventions: Drug: Dexamethasone
Drug: Docetaxel
Biological: Ramucirumab
Drug: Sapanisertib

First Posted Date: 2020-02-13

Last Posted Date: 2020-11-20

Lead Sponsor: SWOG Cancer Research Network

Registration Number: NCT04267913

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Phase 2

Recruiting

Conditions: Stage IIIA Small Intestinal Adenocarcinoma AJCC v8
Stage IV Small Intestinal Adenocarcinoma AJCC v8
Metastatic Small Intestinal Adenocarcinoma
Stage III Small Intestinal Adenocarcinoma AJCC v8
Stage IIIB Small Intestinal Adenocarcinoma AJCC v8

Interventions: Drug: Paclitaxel
Drug: Fluorouracil
Biological: Ramucirumab
Drug: Irinotecan
Drug: Irinotecan Hydrochloride
Drug: Leucovorin
Drug: Leucovorin Calcium

First Posted Date: 2019-12-20

Last Posted Date: 2024-08-16

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 94

Registration Number: NCT04205968

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Swedish Medical Center-Ballard Campus, Seattle, Washington, United States

and more 459 locations

Testing Diet Intervention Versus Non-Diet Intervention for Management of Bowel Symptoms in Rectal Cancer Survivors

Phase 2

Completed

Conditions: Rectal Carcinoma
Rectosigmoid Carcinoma

Interventions: Other: Best Practice
Dietary Supplement: Dietary Intervention
Other: Message
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2019-12-20

Last Posted Date: 2024-05-01

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 95

Registration Number: NCT04205955

Locations: 🇺🇸
UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States
🇺🇸
Mount Carmel East Hospital, Columbus, Ohio, United States
🇺🇸
Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States

and more 223 locations

S1916 Digital Medicine Program for Pain Control in Cancer Patients

Not Applicable

Terminated

Conditions: Metastatic Cancer

Interventions: Drug: Oxycodone/acetaminophen 5/325 mg
Device: Proteus digital medicine program

First Posted Date: 2019-12-11

Last Posted Date: 2023-06-27

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 2

Registration Number: NCT04194528

Locations: 🇺🇸
Decatur Memorial Hospital, Decatur, Illinois, United States
🇺🇸
Carle Cancer Center NCORP, Urbana, Illinois, United States
🇺🇸
Columbia University, New York, New York, United States

and more 2 locations

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

Phase 2

Active, not recruiting

Conditions: Stage IVB Lung Cancer AJCC v8
Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Advanced Lung Non-Squamous Non-Small Cell Carcinoma
Stage IVA Lung Cancer AJCC v8

Interventions: Drug: Avelumab
Drug: Talazoparib
Drug: Talazoparib Tosylate

First Posted Date: 2019-11-22

Last Posted Date: 2024-06-04

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 47

Registration Number: NCT04173507

Locations: 🇺🇸
Parkview Regional Medical Center, Fort Wayne, Indiana, United States
🇺🇸
Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States
🇺🇸
Sanford Bismarck Medical Center, Bismarck, North Dakota, United States

and more 322 locations

S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer

Phase 3

Recruiting

Conditions: Lung Small Cell Carcinoma
Limited Stage Lung Small Cell Carcinoma
Extensive Stage Lung Small Cell Carcinoma

Interventions: Procedure: Magnetic Resonance Imaging
Radiation: Prophylactic Cranial Irradiation

First Posted Date: 2019-11-07

Last Posted Date: 2024-05-03

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 668

Registration Number: NCT04155034

Locations: 🇺🇸
Central Maryland Radiation Oncology in Howard County, Columbia, Maryland, United States
🇺🇸
Aspirus Regional Cancer Center, Wausau, Wisconsin, United States
🇺🇸
Dublin Methodist Hospital, Dublin, Ohio, United States

and more 338 locations

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Daratumumab/rHuPH20

First Posted Date: 2019-08-28

Last Posted Date: 2024-08-23

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 1100

Registration Number: NCT04071457

Locations: 🇺🇸
Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States
🇺🇸
Mount Carmel Health Center West, Columbus, Ohio, United States
🇺🇸
Advocate Illinois Masonic Medical Center, Chicago, Illinois, United States

and more 837 locations

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Phase 2

Active, not recruiting

Conditions: Stage IV Lung Cancer AJCC v8
Recurrent Lung Non-Small Cell Carcinoma
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Interventions: Biological: Pembrolizumab
Drug: Docetaxel
Drug: Gemcitabine
Drug: Gemcitabine Hydrochloride
Drug: Pemetrexed
Drug: Pemetrexed Disodium
Biological: Ramucirumab

First Posted Date: 2019-06-03

Last Posted Date: 2024-06-14

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 166

Registration Number: NCT03971474

Locations: 🇺🇸
Bayhealth Hospital Kent Campus, Dover, Delaware, United States
🇺🇸
Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States
🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States

and more 882 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy